# Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

> **NCT07469306** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 130 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **RADIATION:** Modified Short-course radiotherapy
- **RADIATION:** Long-course radiotherapy
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Tislelizumab
- **DRUG:** Capecitabine
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT07469306
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-10
- **Primary completion:** 2027-08-10
- **Final completion:** 2027-09-01
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07469306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07469306, "Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07469306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*